XALute Trial
Phase 3
675
about 4.6 years
18+
Male only
42 sites in AL, CA, FL +20
What this study is about
Researchers are testing whether xaluritamig, compared to cabazitaxel or another treatment for prostate cancer, helps people live longer. The trial will last about 1694 days and involve approximately 675 participants.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Abiraterone
- 2.Take Cabazitaxel
- 3.Take Enzalutamide
- +1 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
You are randomly assigned, but you will know your treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
abiraterone, cabazitaxel, enzalutamide
injection, intravenous, oral (Oral Tablet)
Primary: Overall Survival (OS)
Secondary: Area Under the Concentration-time Curve (AUC) of Xaluritamig, Change from Baseline in BPI-SF Pain Intensity Scale Score, Change from Baseline in BPI-SF Pain Interference Scale Score, Change from Baseline in Brief Pain Inventory - Short Form (BPI-SF) Worst Pain Score, Change from Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score and Subscale Score, Change from baseline in the EQ-5D-5L Visual Analogue Scale (VAS), Change from baseline in the European Quality of Life 5 Domain 5 Level Scale (EQ-5D-5L) Utility Score, Disease Control Rate per Modified RECIST v1.1 as Assessed by BICR
Oncology